These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 9816172)

  • 1. Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanoma.
    Jakubowski AA; Bajorin DF; Templeton MA; Chapman PB; Cody BV; Thaler H; Tao Y; Filippa DA; Williams L; Sherman ML; Garnick MB; Houghton AN
    Clin Cancer Res; 1996 Feb; 2(2):295-302. PubMed ID: 9816172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects.
    Weiner LM; Li W; Holmes M; Catalano RB; Dovnarsky M; Padavic K; Alpaugh RK
    Cancer Res; 1994 Aug; 54(15):4084-90. PubMed ID: 8033141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of recombinant human macrophage colony-stimulating factor administered by continuous intravenous infusion in patients with metastatic cancer.
    Cole DJ; Sanda MG; Yang JC; Schwartzentruber DJ; Weber J; Ettinghausen SE; Pockaj BA; Kim HI; Levin RD; Pogrebniak HW
    J Natl Cancer Inst; 1994 Jan; 86(1):39-45. PubMed ID: 8271281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony-stimulating factor (rhM-CSF) in patients with metastatic gastrointestinal cancer.
    Saleh MN; Khazaeli MB; Wheeler RH; Bucy RP; Liu T; Everson MP; Munn DH; Schlom J; LoBuglio AF
    Cancer Res; 1995 Oct; 55(19):4339-46. PubMed ID: 7671245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma.
    Minasian LM; Yao TJ; Steffens TA; Scheinberg DA; Williams L; Riedel E; Houghton AN; Chapman PB
    Cancer; 1995 May; 75(9):2251-7. PubMed ID: 7536122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of the GM-CSF antagonist E21R.
    Olver IN; Hercus T; Lopez A; Vadas M; Somogyi AA; Doyle I; Foster DJ; Keefe D; Taylor A; Brown M; To LB; Cole J; Rawling T; Cambareri B; Myers M; Olszewski N; Bastiras S; Senn C; Hey A; Verma M; Wigley P
    Cancer Chemother Pharmacol; 2002 Sep; 50(3):171-8. PubMed ID: 12203098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: a phase I study.
    Sanda MG; Yang JC; Topalian SL; Groves ES; Childs A; Belfort R; de Smet MD; Schwartzentruber DJ; White DE; Lotze MT
    J Clin Oncol; 1992 Oct; 10(10):1643-9. PubMed ID: 1403042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer.
    Robertson MJ; Mier JW; Logan T; Atkins M; Koon H; Koch KM; Kathman S; Pandite LN; Oei C; Kirby LC; Jewell RC; Bell WN; Thurmond LM; Weisenbach J; Roberts S; Dar MM
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4265-73. PubMed ID: 16857801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
    Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
    J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.
    Thompson JA; Curti BD; Redman BG; Bhatia S; Weber JS; Agarwala SS; Sievers EL; Hughes SD; DeVries TA; Hausman DF
    J Clin Oncol; 2008 Apr; 26(12):2034-9. PubMed ID: 18347008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma.
    Ridolfi L; Ridolfi R
    Hepatogastroenterology; 2002; 49(44):335-9. PubMed ID: 11995445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exposure-based safety evaluation of recombinant human macrophage colony-stimulating factor (M-CSF) in cynomolgus monkeys.
    McCabe RD; Childs AL; Reynolds D; Johnson DE
    Toxicol Sci; 1998 May; 43(1):61-7. PubMed ID: 9629620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients.
    Janik JE; Miller LL; Kopp WC; Taub DD; Dawson H; Stevens D; Kostboth P; Curti BD; Conlon KC; Dunn BK; Donegan SE; Ullrich R; Alvord WG; Gause BL; Longo DL
    Clin Immunol; 1999 Dec; 93(3):209-21. PubMed ID: 10600331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia.
    Frankel AE; Powell BL; Hall PD; Case LD; Kreitman RJ
    Clin Cancer Res; 2002 May; 8(5):1004-13. PubMed ID: 12006512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
    Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
    Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of recombinant macrophage colony-stimulating factor by rapid intravenous infusion in patients with cancer.
    Redman BG; Flaherty L; Chou TH; Kraut M; Martino S; Simon M; Valdivieso M; Groves E
    J Immunother (1991); 1992 Jul; 12(1):50-4. PubMed ID: 1637782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effects.
    Bukowski RM; Budd GT; Gibbons JA; Bauer RJ; Childs A; Antal J; Finke J; Tuason L; Lorenzi V; McLain D
    J Clin Oncol; 1994 Jan; 12(1):97-106. PubMed ID: 8270990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma.
    Lutzky J; Weber R; Nunez Y; Gillett M; Spitler L
    J Immunother; 2009 Jan; 32(1):79-85. PubMed ID: 19307996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.